Biocytogen Best Research Paper Award commends typhoid toxin and potential peptide therapy research
Boston, May 27, 2021, adapted from Cornell Chronicle, Graduate students and postdoctoral researchers in the Department of Microbiology and Immunology from Cornell University faced stiff…
Read more
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1
BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi…
Read more
Biocytogen announces acquisition of a third Beacon Optofluidic system
BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument,…
Read more Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with…
Read more
Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement
Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into…
Read more
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China
BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability,…
Read more
Beijing Biocytogen Company Name Change Annuncement
Effective December 29th, 2020, our parent company name has officially changed from Beijing Biocytogen Co., Ltd. to Biocytogen Pharmaceuticals (Beijing) Co., Ltd. There is no…
Read more
Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor
Xencor to use RenLite™ Fully Human Antibody Mouse Platform to discover novel antibody drugs WAKEFIELD, Mass. and BEIJING, Dec. 7, 2020 /PRNewswire/--Beijing Biocytogen Co., Ltd. , Biocytogen Boston…
Read more
Biocytogen Teams With Ina Research To Boost Presence In Japan
Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with…
Read more
Antibody Engineering & Therapeutics Virtual 2020
Agenda Book Now Presentation: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms Speaker: Li Hui, PhD, MD, Scientific Director of Biocytogen Boston…
Read more